Prevention and management of adverse events related to regorafenib

A Phase I Dose-Escalation Study of Regorafenib (BAY 73-4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors

(2012) K. Mross et al.   CLINICAL CANCER RESEARCH

Cancer drugs and the heart: importance and management

(2012) T. M. Suter et al.   EUROPEAN HEART JOURNAL

A Home-Based Exercise Program to Improve Function, Fatigue, and Sleep Quality in Patients With Stage IV Lung and Colorectal Cancer: A Randomized Controlled Trial

(2012) Andrea L. Cheville et al.   JOURNAL OF PAIN AND SYMPTOM MANAGEMENT

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

(2012) George D Demetri et al.   LANCET

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

(2012) Axel Grothey et al.   LANCET

Pyrazinamide-induced maculopapular rash

(2011) Faisal Imam et al.   INDIAN JOURNAL OF DERMATOLOGY

Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

(2010) Scott M. Wilhelm et al.   INTERNATIONAL JOURNAL OF CANCER

Cardiotoxicity of anticancer treatments: what the cardiologist needs to know

(2010) Michael S. Ewer et al.   Nature Reviews Cardiology